igf 1 lr3 studies IGF-1 – Peptides Collective IGF-1 LR3 in Aesthetic and

Both were placed on FDA Category 2 in September 2023, removed in September 2024 after withdrawn nominations, and reviewed by PCAC in late 2024 with FDA recommending against 503A Bulks inclusion

Dosing a short-acting GHRH analog (sermorelin, no-DAC CJC) at bedtime stacks the peptides pulse on top of the natural one, amplifying it rather than fighting it

This is a reversible modification and adding sodium borohydride (NaBH4) results in the GSH release, which can subsequently react with DTNB and be measured

Mller J, Jrgensen JO, Mller N, et al

Verify current status against FDAs own listings rather than any secondary source, including this one

Delivered via nasal spray for fast absorption, it supports energy, brain clarity, and cellular repairmaking it a favorite among professionals, parents, and high-performers